Axon Enterprise Inc is building a public safety operating system by integrating a suite of hardware devices and cloud software solutions... Show more
Axon Enterprise, Inc. develops integrated technology and weapons systems for public safety and law enforcement agencies worldwide. The company's product ecosystem spans two core segments: Connected Devices and Software and Services. Its hardware lineup includes conducted energy weapons sold under the TASER brand, body-worn cameras, in-car camera systems, and drone and counter-drone technologies. These devices are paired with a cloud-based software platform that includes Axon Evidence, the AI-powered Draft One report-writing tool, Axon Records, Axon Fusus real-time crime center capabilities, and Axon Assistant. Headquartered in Scottsdale, Arizona, and founded in 1993, Axon has evolved from a hardware-centric business into a software and data platform for public safety. Investors closely track the company due to its dominant position in the law enforcement technology market, recurring subscription revenue model, and expansion into adjacent categories such as drones and real-time analytics.
Over the 30-day period ending July 31, 2026, Axon shares fell roughly 11%, sliding from approximately $594–$597 in early July to $527.76. The decline was particularly pronounced after the stock hit an intra-session peak near $665 in the first full week of July, only to reverse sharply in the following sessions. Profit-taking, combined with downward pressure from insider selling disclosures and tempered analyst commentary, weighed on near-term sentiment. By mid-to-late July, the stock had stabilized in the $510–$550 range, finding support near its 50-day moving average.
Zooming out to the trailing three months, however, Axon's performance tells a different story. From early May 2026 through the end of July, the stock rose approximately 31%, climbing from levels near $400 to over $525. The broader quarterly advance was powered by a strong first-quarter earnings report in early May, upbeat guidance, and several analyst price-target increases amid accelerating adoption of Axon's software and connected-device bundles.
Several factors converged to drive Axon's 30-day pullback. First, the stock's rapid climb in late June and early July—during which it surged from roughly $460 to above $640 in a matter of weeks—prompted natural profit-taking. The velocity of that rally, partly fueled by AI enthusiasm and expectations around federal contracting opportunities, left shares vulnerable to a correction.
Second, insider selling activity drew significant investor attention. CEO Patrick W. Smith sold 10,000 shares on July 7 at an average price of roughly $644 under a pre-arranged 10b5-1 trading plan. President Joshua Isner also sold 13,000 shares in early June at an average price near $488. All told, insiders sold approximately 59,000 shares worth about $30.5 million over the last quarter, according to SEC filings.
Third, select analyst notes introduced caution. UBS Group lowered its Axon price target to $440 from $570 and maintained a "Neutral" rating in early May, while Barclays trimmed its target from $682 to $523 while keeping an "Overweight" rating. Although firms including Needham (target raised to $750) and Piper Sandler (target raised to $724) remain bullish, the mixed signals reinforced a wait-and-see stance among some market participants.
Finally, broader market dynamics played a role. Rotation out of high-multiple growth names and into value-oriented sectors, coupled with uncertainty around federal budget priorities, contributed to the near-term selling pressure on Axon shares.
Over the past quarter, Axon's stock posted a robust gain of roughly 31%, driven primarily by strong fundamentals and expanding confidence in the company's software transformation. On May 6, Axon reported first-quarter 2026 results that exceeded expectations: revenue rose 33.7% year-over-year to $807.35 million, beating consensus estimates of roughly $779 million, while earnings per share of $1.61 edged past the $1.60 consensus. The results underscored sustained demand for Axon's integrated hardware-software bundles and growing adoption of newer products such as TASER 10, Axon Body 4, and the Draft One AI report-writing tool.
Analyst optimism, particularly around Axon's subscription-based revenue streams and international expansion pipeline, further supported the stock. Several research firms raised price targets during the quarter, and institutional investors—including Baillie Gifford, Wellington Management, and Sands Capital—increased their stakes. The quarterly advance highlights that Axon's broader narrative remains anchored in long-term secular demand for public safety technology modernization, even as short-term price swings reflect tactical repositioning.
For traders looking to navigate volatile markets with data-driven precision, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing AI trading bots. Tickeron hosts hundreds of automated trading bots that actively trade thousands of tickers, but only those demonstrating the most compelling recent performance and relevance appear in this trending section. Each bot operates with distinct strategies, timeframes, and performance metrics—ranging from short-term swing trading to longer-duration trend-following models—allowing users to explore approaches aligned with their own trading preferences. The page provides a practical starting point for those interested in evaluating how algorithmic trading systems interpret real-time market data and execute trades across diverse market conditions.
Axon's second-quarter 2026 earnings report, scheduled for August 5, 2026, stands as the most immediate catalyst. Investors will closely scrutinize revenue growth, software and services segment performance, margin trends, and forward guidance. Key metrics to watch include subscription revenue expansion, average deal sizes, and any commentary on international contract momentum.
Beyond earnings, several themes warrant attention. The integration and scaling of recently launched products—including Draft One, Dedrone counter-drone technology, and Axon Fusus—could meaningfully affect the long-term growth trajectory. Federal and state-level public safety budget allocations, particularly around nonlethal enforcement technologies, remain a critical macro driver. Additionally, competitive dynamics in the AI-powered law enforcement software space and potential regulatory shifts around surveillance and data privacy may influence Axon's addressable market and valuation. While the analyst consensus remains favorable, continued insider selling activity or further target revisions could shape sentiment in the weeks following the earnings release.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Moving Average Convergence Divergence (MACD) for AXON turned positive on August 04, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 31, 2026. You may want to consider a long position or call options on AXON as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in of 371 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 260 cases where AXON Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AXON broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.850) is normal, around the industry mean (10.705). AXON has a moderately high P/E Ratio (244.839) as compared to the industry average of (64.198). Projected Growth (PEG Ratio) (4.801) is also within normal values, averaging (8.304). Dividend Yield (0.000) settles around the average of (0.016) among similar stocks. P/S Ratio (16.807) is also within normal values, averaging (36.455).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a clinical-stage biopharmaceutical company
Industry AerospaceDefense